


Listing of Claims

The following listing of Claims will replace all prior versions and listings of Claims in the Application.

Claims

1-14(Cancelled)

15. (Withdrawn) A compound of formula (Ib):



wherein  $R^a$  is selected from halogen, hydroxy, cyano, nitro, amino, hydroxycarbonyl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkenyl,  $C_1$ - $C_6$  alkynyl, hydroxy $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy $C_1$ - $C_6$  alkyl, perfluoro $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkylamino, di-  $C_1$ - $C_6$  alkylamino, amino $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkylamino $C_1$ - $C_6$  alkyl, di- $C_1$ - $C_6$  alkylamino $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  acyl,  $C_1$ - $C_6$  acyloxy,  $C_1$ - $C_6$  acyloxy $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  acylamino,  $C_1$ - $C_6$  alkylthio,  $C_1$ - $C_6$  alkylthiocarbonyl,  $C_1$ - $C_6$  alkylthiooxo,  $C_1$ - $C_6$  alkoxycarbonyl,  $C_1$ - $C_6$  alkylsulfonyl,  $C_1$ - $C_6$  alkylsulfonylamino, aminosulfonyl,  $C_1$ - $C_6$  alkylaminosulfonyl, di- $C_1$ - $C_6$  alkylaminosulfonyl, 3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;

$R^b$  is selected from hydrogen, halogen, hydroxy, ( $C_1$ - $C_6$ )alkoxy cyano, nitro, amino, hydroxycarbonyl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkenyl,  $C_1$ - $C_6$  alkynyl,  $C_1$ - $C_6$  alkoxy, hydroxy $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy $C_1$ - $C_6$  alkyl, perfluoro  $C_1$ - $C_6$  alkyl, perfluoro $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkylamino, di-  $C_1$ - $C_6$  alkylamino, amino $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkylamino $C_1$ - $C_6$  alkyl, di- $C_1$ - $C_6$  alkylamino $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  acyl,  $C_1$ - $C_6$  acyloxy,  $C_1$ - $C_6$  acyloxy $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  acylamino,

C<sub>1</sub>-C<sub>6</sub> alkylthio, C<sub>1</sub>-C<sub>6</sub> alkylthiocarbonyl, C<sub>1</sub>-C<sub>6</sub> alkylthioxo, C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>6</sub> alkylsulfonylamino, aminosulfonyl, C<sub>1</sub>-C<sub>6</sub> alkylaminosulfonyl, di-C<sub>1</sub>-C<sub>6</sub> alkylaminosulfonyl, 3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl;  
or a pharmaceutically acceptable salt thereof.

16-17 (canceled)

18. (Withdrawn) A compound of formula (1b) according to claim 15 which is selected from the group consisting of:

(2*S*,4*S*)-4-(3-Fluoro-benzyl)-pyrrolidine-2-carboxylic acid;  
(2*S*,4*S*)-4-(2,3-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid; and  
(2*S*,4*S*)-4-(2,5-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid; or a pharmaceutically acceptable salt thereof.

19. (canceled)

20. (Withdrawn) A pharmaceutical composition comprising a compound of formula (1b) according to claim 15, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

21. (Withdrawn) A pharmaceutical composition comprising a compound of formula (1b) according to claim 15, or a pharmaceutically acceptable salt thereof, and at least one other therapeutically active agent.

22. (Withdrawn, currently amended) A combination according to claim 21, wherein the other therapeutically active agent is a PDEV inhibitor selected from sildenafil, vardenafil, tadalafil, 1-[6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridylsulfonyl]-4-ethylpiperazine, 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

23-26. (canceled) A pharmaceutical composition comprising a compound of formula (1c) according to claim 16, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

27. (New) The compound (2*S*,4*S*)-4-(3-Fluoro-benzyl)-pyrrolidine-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

28. (New) The compound (2*S*,4*S*)-4-(2,3-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid, a pharmaceutically acceptable salt thereof.

29. (New) The compound (2*S*,4*S*)-4-(2,5-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.